Join our daily newsletter At The Bell to receive exclusive market insights
- Little Green Pharma (LGP) delivers its first shipment of a high-THC medicinal cannabis flower product from its Danish facility to Ilios Santé in Germany
- LGP first signed a two-year, $2.3 million commercial agreement with Illois Santé in July 2022
- LGP says the new shipment represents the culmination of a nine-month engagement process that included obtaining licences, vendor qualification and a quality assurance audit
- The shipment follows a recent delivery of 30 kilograms of high-THC flower to Demecan, also based in Germany, in February
- Little Green Pharma shares are up 2.78 per cent and trading at 18.5 cents at 10:32 am AEDT
Little Green Pharma (LGP) has delivered its first shipment of a high-THC medicinal cannabis flower product from its Danish facility to Ilios Santé in Germany.
Ilios Santé is a European good distribution practice (GDP)-licensed pharmaceutical wholesaler headquartered in Frankfurt. The company is a wholly-owned subsidiary of The Bloomwell Group, a European medicinal cannabis healthcare conglomerate.
LGP first signed a two-year, $2.3 million commercial agreement with Ilios Santé in July 2022. Roughly 80 per cent of the minimum quantities of the contract fall within the second year.
LGP told investors the long lead-time between signing commercial terms and the first shipment was due to the extensive quality and regulatory requirements associated with shipping pharmaceuticals between countries.
The company said the new shipment represented the culmination of a nine-month engagement process that included obtaining licences, vendor qualification and a quality assurance audit.
The new LGP shipment follows a recent delivery of 30 kilograms of high-THC flower delivered by the Danish facility to Demecan, also based in Germany, in February.
Little Green Pharma shares were up 2.78 per cent and trading at 18.5 cents at 10:32 am AEDT.
